Crown Laboratories, Inc., a privately held player in the skincare industry, agreed on Monday to acquire Revance Therapeutics, Inc. (NASDAQ:RVNC). Under the terms of the agreement, Crown will commence ...
After debuting in the aesthetics market with Daxxify last year, Revance has made its way to the potentially lucrative therapeutic space. With a Monday FDA nod to treat cervical dystonia in adults, ...
The battle between the makers of face-filling beauty products is getting ugly. Now, AbbVie is throwing a new wrinkle into the mix. The pharma giant is accusing Revance of recruiting key employees as ...
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced the appointment of ...
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (NASDAQ: RVNC) (“Revance,” the “Company” or “our”), today reported financial results for the third quarter ended September 30, 2024 and ...
U.S. District Judge Eli Richardson in Nashville, Tennessee, ruled, opens new tab that Allergan plausibly alleged that Revance had acquired and used some of its rival’s trade secrets amid a series of ...
Revance Announces Publication of SAKURA 1 and SAKURA 2 Results in Plastic and Reconstructive Surgery
- Results show DaxibotulinumtoxinA for Injection (DAXI) can reduce frown lines for 24 weeks (approximately 6 months) or more - This manuscript presents the findings from SAKURA 1 and 2 side-by-side, ...
Shares of Revance Therapeutics surged 18% Thursday after the company announced the Food and Drug Administration had approved Daxxify, a facial injection drug that Revance hopes will challenge Botox’s ...
The MarketWatch News Department was not involved in the creation of this content. NASHVILLE, Tenn., March 25, 2026 /PRNewswire/ -- Revance, a fast-growing global aesthetics, regenerative and consumer ...
Shares of Revance Therapeutics (RVNC +0.00%) are up by a respectable 15.8% as of 11:08 a.m. EDT Wednesday morning. The biopharma's stock is regaining some of its lost ground after yesterday's ...
Revance Therapeutics Inc (NASDAQ:RVNC) is plummeting today, last seen down 41.9% to trade at $13.21. This plunge came after news that the U.S. Food and Drug Administration (FDA) declined to approve ...
Jan 4 (Reuters) - A federal judge on Wednesday said Botox maker AbbVie's ABBV.N Allergan unit can move ahead with its lawsuit accusing Revance Therapeutics RVNC.O of taking its confidential data to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results